\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\:\\ \\ bilateral\\ proptosis\\,\\ mild\\ periorbital\\ edema\\,\\ sclera\\ clear\\,\\ perrla\\,\\ eomi\\,\\ no\\ discharge\ \(0\)\
\-\ treatment\\ for\\ grave\\'s\\ ophthalmopathy\\ depends\\ on\\ severity\\ of\\ symptoms\\.\\ \\ if\\ present\\,\\ treat\\ hyperthyroidism\\ with\\ methimazole\\.\\ \\ for\\ mild\\ involvement\\ including\\ dry\\,\\ irritated\\ eyes\\,\\ natural\\ tears\\ are\\ helpful\\ during\\ the\\ day\\ and\\ an\\ eye\\ lubricant\\ \\(methycellulose\\)\\ is\\ appropriate\\ at\\ night\\.\\ \\ for\\ moderate\\ disease\\ that\\ can\\ include\\ conjunctival\\ erythema\\,\\ progressive\\ proptosis\\,\\ and\\ diplopia\\,\\ prednisone\\ 30mg\\ daily\\ for\\ 4\\ weeks\\ should\\ be\\ initiated\\ additionally\\.\\ \\ \ \(0\)\
\-\ external\\ radiation\\ may\\ be\\ used\\ in\\ conjunction\\ with\\ prednisone\\ if\\ high\\ dose\\ is\\ contraindicated\\ or\\ not\\ tolerated\\ in\\ the\\ case\\ of\\ persistent\\ orbital\\ edema\\.\\ \\ \ \(0\)\
\-\ in\\ severe\\ disease\\ in\\ which\\ the\\ patient\\ presents\\ with\\ threatened\\ loss\\ or\\ complete\\ loss\\ of\\ vision\\,\\ initial\\ pulse\\ therapy\\ with\\ intravenous\\ methylprednisone\\ or\\ immediate\\ intramuscular\\ dexamethasone\\ 4mg\\ may\\ be\\ done\\ before\\ urgent\\ orbital\\ decompression\\ surgery\\.\\ \\ surgery\\ is\\ also\\ indicated\\ for\\ refractory\\ disease\\ despite\\ glucocorticoids\\ or\\ cosmetic\\ correction\\ of\\ severe\\ proptosis\\.\\ \\ \ \(0\)\
\-\ the\\ orbit\\ may\\ be\\ decompressed\\ transantrally\\,\\ which\\ involves\\ removal\\ of\\ medial\\ wall\\ and\\ floor\\ of\\ the\\ orbits\\.\\ \\ this\\ procedure\\ is\\ preferred\\ over\\ others\\ because\\ it\\ does\\ not\\ involve\\ craniotomy\\ or\\ extensive\\ scarring\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ follow\\-up\\ should\\ include\\ monthly\\ clinic\\ visits\\ that\\ may\\ be\\ progressively\\ spaced\\ out\\ to\\ 3\\ months\\,\\ 6\\ months\\,\\ or\\ 12\\ months\\ \\-\\ depending\\ on\\ patient\\'s\\ clinical\\ course\\ and\\ severity\\ of\\ disease\\.\\ \\ regular\\ follow\\-up\\ with\\ ophthalmology\\,\\ endocrinology\\,\\ and\\ surgery\\ as\\ needed\\,\\ particularly\\ if\\ patient\\ has\\ persistent\\ or\\ worsening\\ symptoms\\,\\ and\\ especially\\ if\\ disease\\ complications\\ are\\ anticipated\\.\ \(0\)\
\-\ \\â\\€\\¢\\ bilateral\\ proptosis\\ and\\ periorbital\\ tissue\\ edema\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ inferior\\ recti\\ muscles\ \(0\)\
\-\ \\â\\€\\¢\\ increased\\ periorbital\\ fat\\ distribution\ \(0\)\
\-\ \\â\\€\\¢\\ bellies\\ of\\ medial\\ recti\\ enlarged\\ with\\ normal\\ tapering\\ of\\ tendons\\.\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ superior\\,\\ medial\\,\\ inferior\\ rectus\\ muscles\ \(0\)\
\-\ grave\\'s\\ ophthalmopathy\ \(0\)\
\-\ \\â\\€\\¢\\ periorbital\\ \\/\\ orbital\\ cellulitis\ \(0\)\
\-\ \\â\\€\\¢\\ histiocytosis\ \(0\)\
\-\ \\â\\€\\¢\\ orbital\\ myositis\\ \\/\\ orbital\\ pseudotumor\ \(0\)\
\-\ \\â\\€\\¢\\ grave\\â\\€\\™s\\ orbitopathy\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ 45\\ year\\-old\\ man\\ with\\ a\\ past\\ history\\ of\\ malignant\\ testicular\\ neoplasm\\ and\\ hashimoto\\â\\€\\™s\\ thyroiditis\\,\\ presents\\ now\\ with\\ a\\ several\\-month\\ history\\ of\\ worsening\\ eye\\ swelling\\,\\ dryness\\,\\ and\\ irritation\\,\\ gradually\\ progressing\\ to\\ lid\\ retraction\\ and\\ intermittent\\ blurry\\ vision\\,\\ prompting\\ a\\ referral\\ to\\ ophthalmology\\.\\ \\ he\\ denies\\ recent\\ trauma\\,\\ fever\\,\\ chills\\,\\ nausea\\,\\ headaches\\.\ \(0\)\
\-\ the\\ patient\\ has\\ grave\\â\\€\\™s\\ ophthalmopathy\\,\\ but\\ he\\ does\\ not\\ have\\ symptoms\\ of\\ hyperthyroidism\\ such\\ as\\ heat\\ intolerance\\,\\ tachycardia\\,\\ heart\\ palpitations\\,\\ tremors\\,\\ anxiousness\\,\\ and\\ unintentional\\ weight\\ loss\\.\\ \\ rather\\,\\ he\\ is\\ clinically\\ hypothyroid\\ and\\ requires\\ synthroid\\ treatment\\.\\ \\ with\\ his\\ past\\ history\\ of\\ hashimoto\\'s\\ thyroiditis\\ and\\ subsequent\\ thyroid\\ ablation\\ therapy\\,\\ the\\ patient\\ may\\ have\\ little\\ functional\\ thyroid\\ tissue\\ left\\ for\\ clinical\\ manifestations\\ of\\ hyperthyroidism\\ as\\ a\\ result\\ of\\ his\\ grave\\'s\\ disease\\.\\ \\ however\\,\\ the\\ thyroid\\ stimulating\\ hormone\\ receptor\\ \\(tshr\\)\\ autoantibodies\\ are\\ still\\ circulating\\ and\\ affect\\ other\\ cell\\ types\\ with\\ tshr\\ antigens\\ such\\ as\\ fibroblasts\\,\\ adipocytes\\,\\ and\\ t\\-cells\\ contributing\\ to\\ tissue\\ proliferation\\,\\ inflammation\\ and\\ edema\\ consistent\\ with\\ grave\\'s\\ ophthalmopathy\\ and\\ pretibial\\ myxedema\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ grave\\:\\ 0\\.3301908848035668\ \(0\)\
\-\ ophthalmopathy\\:\\ 0\\.21787738475808657\ \(0\)\
\-\ periorbital\\:\\ 0\\.201513787428484\ \(0\)\
\-\ orbital\\:\\ 0\\.1898782558572595\ \(0\)\
\-\ proptosis\\:\\ 0\\.17472500269029345\ \(0\)\
\-\ and\\:\\ 0\\.1520893019783082\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.1460544663698056\ \(0\)\
\-\ tshr\\:\\ 0\\.13847700113934444\ \(0\)\
\-\ recti\\:\\ 0\\.13232216734054741\ \(0\)\
\-\ of\\:\\ 0\\.12709027756438834\ \(0\)\
\-\ disease\\:\\ 0\\.10904280065528822\ \(0\)\
\-\ may\\:\\ 0\\.1089376284001081\ \(0\)\
\-\ hashimoto\\:\\ 0\\.10789140212197221\ \(0\)\
\-\ or\\:\\ 0\\.10543148075503109\ \(0\)\
\-\ edema\\:\\ 0\\.10328890726425956\ \(0\)\
\-\ ophthalmology\\:\\ 0\\.10207769926141817\ \(0\)\
\-\ thyroid\\:\\ 0\\.1020746280452304\ \(0\)\
\-\ if\\:\\ 0\\.10062242162872327\ \(0\)\
\-\ thyroiditis\\:\\ 0\\.09592286546262112\ \(0\)\
\-\ with\\:\\ 0\\.09325522358162934\ \(0\)\
\-\ prednisone\\:\\ 0\\.09121481044774002\ \(0\)\
\-\ enlarged\\:\\ 0\\.08854480752723272\ \(0\)\
\-\ be\\:\\ 0\\.08781572285443781\ \(0\)\
\-\ severity\\:\\ 0\\.08540110758718598\ \(0\)\
\-\ medial\\:\\ 0\\.08454573615942192\ \(0\)\
\-\ loss\\:\\ 0\\.0791311253363245\ \(0\)\
\-\ for\\:\\ 0\\.07873471434573018\ \(0\)\
\-\ he\\:\\ 0\\.07691354721071822\ \(0\)\
\-\ months\\:\\ 0\\.07560398249094741\ \(0\)\
\-\ vision\\:\\ 0\\.07499478515708632\ \(0\)\
\-\ muscles\\:\\ 0\\.07420458582895065\ \(0\)\
\-\ symptoms\\:\\ 0\\.07106609442527681\ \(0\)\
\-\ patient\\:\\ 0\\.07040882668759468\ \(0\)\
\-\ surgery\\:\\ 0\\.06983204297329433\ \(0\)\
\-\ as\\:\\ 0\\.06957292423279877\ \(0\)\
\-\ eye\\:\\ 0\\.06927088756784525\ \(0\)\
\-\ methycellulose\\:\\ 0\\.06923850056967222\ \(0\)\
\-\ transantrally\\:\\ 0\\.06923850056967222\ \(0\)\
\-\ anxiousness\\:\\ 0\\.06923850056967222\ \(0\)\
\-\ adipocytes\\:\\ 0\\.06923850056967222\ \(0\)\
\-\ the\\:\\ 0\\.06911173978299182\ \(0\)\
\-\ tissue\\:\\ 0\\.06813510775232627\ \(0\)\
\-\ persistent\\:\\ 0\\.06671672942967545\ \(0\)\
\-\ lubricant\\:\\ 0\\.06616108367027371\ \(0\)\
\-\ methylprednisone\\:\\ 0\\.06616108367027371\ \(0\)\
\-\ dryness\\:\\ 0\\.06616108367027371\ \(0\)\
\-\ autoantibodies\\:\\ 0\\.06616108367027371\ \(0\)\
\-\ worsening\\:\\ 0\\.06612395480126103\ \(0\)\
\-\ myxedema\\:\\ 0\\.06397762163195465\ \(0\)\
\-\ methimazole\\:\\ 0\\.0622839968981022\ \(0\)\
\-\ irritated\\:\\ 0\\.0622839968981022\ \(0\)\
\-\ 30mg\\:\\ 0\\.0622839968981022\ \(0\)\
\-\ threatened\\:\\ 0\\.0622839968981022\ \(0\)\
\-\ 4mg\\:\\ 0\\.0622839968981022\ \(0\)\
\-\ spaced\\:\\ 0\\.0622839968981022\ \(0\)\
\-\ bellies\\:\\ 0\\.06090020473255613\ \(0\)\
\-\ hypothyroid\\:\\ 0\\.06090020473255613\ \(0\)\
\-\ antigens\\:\\ 0\\.06090020473255613\ \(0\)\
\-\ does\\:\\ 0\\.0598618436096215\ \(0\)\
\-\ orbitopathy\\:\\ 0\\.05973022512723921\ \(0\)\
\-\ pretibial\\:\\ 0\\.05973022512723921\ \(0\)\
\-\ is\\:\\ 0\\.05928346647348731\ \(0\)\
\-\ inferior\\:\\ 0\\.05890891735634673\ \(0\)\
\-\ dexamethasone\\:\\ 0\\.058716742694237094\ \(0\)\
\-\ anticipated\\:\\ 0\\.058716742694237094\ \(0\)\
\-\ circulating\\:\\ 0\\.058716742694237094\ \(0\)\
\-\ tremors\\:\\ 0\\.057822787833157606\ \(0\)\
\-\ fibroblasts\\:\\ 0\\.057822787833157606\ \(0\)\
\-\ should\\:\\ 0\\.056500271657892766\ \(0\)\
\-\ past\\:\\ 0\\.05636382410628127\ \(0\)\
\-\ conjunctival\\:\\ 0\\.05629972856842665\ \(0\)\
\-\ such\\:\\ 0\\.05569939910156095\ \(0\)\
\-\ monthly\\:\\ 0\\.055639325794838566\ \(0\)\
\-\ unintentional\\:\\ 0\\.055639325794838566\ \(0\)\
\-\ stimulating\\:\\ 0\\.055639325794838566\ \(0\)\
\-\ prompting\\:\\ 0\\.0550318141339278\ \(0\)\
\-\ synthroid\\:\\ 0\\.0550318141339278\ \(0\)\
\-\ receptor\\:\\ 0\\.0550318141339278\ \(0\)\
\-\ clinical\\:\\ 0\\.05487696488010765\ \(0\)\
\-\ severe\\:\\ 0\\.05481550856981374\ \(0\)\
\-\ blurry\\:\\ 0\\.05446934618952164\ \(0\)\
\-\ cosmetic\\:\\ 0\\.053945701060986104\ \(0\)\
\-\ intramuscular\\:\\ 0\\.053455863756519534\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.053455863756519534\ \(0\)\
\-\ decompressed\\:\\ 0\\.053455863756519534\ \(0\)\
\-\ visits\\:\\ 0\\.053455863756519534\ \(0\)\
\-\ endocrinology\\:\\ 0\\.053455863756519534\ \(0\)\
\-\ lid\\:\\ 0\\.053455863756519534\ \(0\)\
\-\ contraindicated\\:\\ 0\\.052995732337152684\ \(0\)\
\-\ urgent\\:\\ 0\\.052995732337152684\ \(0\)\
\-\ his\\:\\ 0\\.05251502841370443\ \(0\)\
\-\ sclera\\:\\ 0\\.051762239022667064\ \(0\)\
\-\ tapering\\:\\ 0\\.051762239022667064\ \(0\)\
\-\ include\\:\\ 0\\.05152053712432861\ \(0\)\
\-\ conjunction\\:\\ 0\\.05139192929012311\ \(0\)\
\-\ not\\:\\ 0\\.051275782533288954\ \(0\)\
\-\ irritation\\:\\ 0\\.051038849630709086\ \(0\)\
\-\ palpitations\\:\\ 0\\.050701467689308985\ \(0\)\
\-\ contributing\\:\\ 0\\.050701467689308985\ \(0\)\
\-\ depends\\:\\ 0\\.050378446857121\ \(0\)\
\-\ natural\\:\\ 0\\.050378446857121\ \(0\)\
\-\ progressing\\:\\ 0\\.0500686142888146\ \(0\)\
\-\ therapy\\:\\ 0\\.04975183698899757\ \(0\)\
\-\ history\\:\\ 0\\.049623854477481855\ \(0\)\
\-\ are\\:\\ 0\\.04928571389778971\ \(0\)\
\-\ perrla\\:\\ 0\\.049208467251804076\ \(0\)\
\-\ mild\\:\\ 0\\.04908567160163922\ \(0\)\
\-\ orbits\\:\\ 0\\.04894212961029093\ \(0\)\
\-\ tolerated\\:\\ 0\\.04819498481880197\ \(0\)\
\-\ myositis\\:\\ 0\\.04819498481880197\ \(0\)\
\-\ retraction\\:\\ 0\\.04819498481880197\ \(0\)\
\-\ heat\\:\\ 0\\.04796143273131056\ \(0\)\
\-\ intolerance\\:\\ 0\\.04773485339943512\ \(0\)\
\-\ refractory\\:\\ 0\\.04751484251795161\ \(0\)\
\-\ initiated\\:\\ 0\\.04730102995772248\ \(0\)\
\-\ ablation\\:\\ 0\\.04730102995772248\ \(0\)\
\-\ eomi\\:\\ 0\\.04709307601913057\ \(0\)\
\-\ tendons\\:\\ 0\\.046693518296811704\ \(0\)\
\-\ bilateral\\:\\ 0\\.0465369100904038\ \(0\)\
\-\ proliferation\\:\\ 0\\.0465013600849495\ \(0\)\
\-\ craniotomy\\:\\ 0\\.046313947008567995\ \(0\)\
\-\ preferred\\:\\ 0\\.04595245754889835\ \(0\)\
\-\ tears\\:\\ 0\\.04577797069299152\ \(0\)\
\-\ dry\\:\\ 0\\.04560740522387001\ \(0\)\
\-\ others\\:\\ 0\\.04560740522387001\ \(0\)\
\-\ cellulitis\\:\\ 0\\.04544058875159142\ \(0\)\
\-\ diplopia\\:\\ 0\\.04527736000991811\ \(0\)\
\-\ gradually\\:\\ 0\\.04511756791940344\ \(0\)\
\-\ pseudotumor\\:\\ 0\\.04496107074708862\ \(0\)\
\-\ rectus\\:\\ 0\\.044807735351097035\ \(0\)\
\-\ affect\\:\\ 0\\.044807735351097035\ \(0\)\
\-\ scarring\\:\\ 0\\.04465743650003659\ \(0\)\
\-\ correction\\:\\ 0\\.044510056258492664\ \(0\)\
\-\ manifestations\\:\\ 0\\.04436548343105663\ \(0\)\
\-\ referral\\:\\ 0\\.04422361305832395\ \(0\)\
\-\ tachycardia\\:\\ 0\\.04422361305832395\ \(0\)\
\-\ hormone\\:\\ 0\\.04408434595913906\ \(0\)\
\-\ treat\\:\\ 0\\.04381325128584739\ \(0\)\
\-\ floor\\:\\ 0\\.04381325128584739\ \(0\)\
\-\ histiocytosis\\:\\ 0\\.04342394318555097\ \(0\)\
\-\ to\\:\\ 0\\.04329489132174064\ \(0\)\
\-\ have\\:\\ 0\\.04325668589266781\ \(0\)\
\-\ in\\:\\ 0\\.043081793956321834\ \(0\)\
\-\ little\\:\\ 0\\.0425864186509943\ \(0\)\
\-\ functional\\:\\ 0\\.04247397446171756\ \(0\)\
\-\ progressively\\:\\ 0\\.04236317185219289\ \(0\)\
\-\ eyes\\:\\ 0\\.04204015102000491\ \(0\)\
\-\ requires\\:\\ 0\\.04193546185741099\ \(0\)\
\-\ decompression\\:\\ 0\\.041832197081413\ \(0\)\
\-\ presents\\:\\ 0\\.04165448232522707\ \(0\)\
\-\ immediate\\:\\ 0\\.041432639359094144\ \(0\)\
\-\ treatment\\:\\ 0\\.04124763216491669\ \(0\)\
\-\ depending\\:\\ 0\\.04124048114723193\ \(0\)\
\-\ helpful\\:\\ 0\\.04105306807085043\ \(0\)\
\-\ daily\\:\\ 0\\.04105306807085043\ \(0\)\
\-\ pulse\\:\\ 0\\.04087017141468798\ \(0\)\
\-\ particularly\\:\\ 0\\.04087017141468798\ \(0\)\
\-\ testicular\\:\\ 0\\.04060383377317484\ \(0\)\
\-\ dose\\:\\ 0\\.04043132989414516\ \(0\)\
\-\ types\\:\\ 0\\.04026265975377721\ \(0\)\
\-\ orbit\\:\\ 0\\.04009765664764131\ \(0\)\
\-\ has\\:\\ 0\\.03955200046497752\ \(0\)\
\-\ intravenous\\:\\ 0\\.03947133495491163\ \(0\)\
\-\ chills\\:\\ 0\\.03939655756231902\ \(0\)\
\-\ which\\:\\ 0\\.039373545061742676\ \(0\)\
\-\ erythema\\:\\ 0\\.03917654668083551\ \(0\)\
\-\ night\\:\\ 0\\.03889278114658068\ \(0\)\
\-\ discharge\\:\\ 0\\.03882346702142149\ \(0\)\
\-\ rather\\:\\ 0\\.038355222459695616\ \(0\)\
\-\ still\\:\\ 0\\.038355222459695616\ \(0\)\
\-\ involve\\:\\ 0\\.03810007762946351\ \(0\)\
\-\ appropriate\\:\\ 0\\.03803760942535249\ \(0\)\
\-\ despite\\:\\ 0\\.03767322694336684\ \(0\)\
\-\ involves\\:\\ 0\\.03767322694336684\ \(0\)\
\-\ that\\:\\ 0\\.037577013665826976\ \(0\)\
\-\ regular\\:\\ 0\\.037382392742812895\ \(0\)\
\-\ distribution\\:\\ 0\\.036726747001003326\ \(0\)\
\-\ clinic\\:\\ 0\\.03646943951398094\ \(0\)\
\-\ clinically\\:\\ 0\\.035979602209514364\ \(0\)\
\-\ pe\\:\\ 0\\.03579218913313287\ \(0\)\
\-\ needed\\:\\ 0\\.03574605012202296\ \(0\)\
\-\ additionally\\:\\ 0\\.03565460511277827\ \(0\)\
\-\ indicated\\:\\ 0\\.035609292476970415\ \(0\)\
\-\ intermittent\\:\\ 0\\.03538670045485527\ \(0\)\
\-\ external\\:\\ 0\\.03500178081605964\ \(0\)\
\-\ before\\:\\ 0\\.03500178081605964\ \(0\)\
\-\ denies\\:\\ 0\\.034918830876156284\ \(0\)\
\-\ inflammation\\:\\ 0\\.03479608139818954\ \(0\)\
\-\ 45\\:\\ 0\\.03471533761589093\ \(0\)\
\-\ procedure\\:\\ 0\\.034517158107438294\ \(0\)\
\-\ done\\:\\ 0\\.034439312871653485\ \(0\)\
\-\ especially\\:\\ 0\\.03424812281387821\ \(0\)\
\-\ extensive\\:\\ 0\\.033358364714837725\ \(0\)\
\-\ nausea\\:\\ 0\\.03325827741011483\ \(0\)\
\-\ progressive\\:\\ 0\\.033159492797138236\ \(0\)\
\-\ complications\\:\\ 0\\.033159492797138236\ \(0\)\
\-\ removal\\:\\ 0\\.03309434352197805\ \(0\)\
\-\ subsequent\\:\\ 0\\.03277673048763492\ \(0\)\
\-\ moderate\\:\\ 0\\.032501816750345844\ \(0\)\
\-\ used\\:\\ 0\\.03241234800564927\ \(0\)\
\-\ result\\:\\ 0\\.03241234800564927\ \(0\)\
\-\ headaches\\:\\ 0\\.032294673649205075\ \(0\)\
\-\ course\\:\\ 0\\.031980171844236994\ \(0\)\
\-\ clear\\:\\ 0\\.03138775577224314\ \(0\)\
\-\ involvement\\:\\ 0\\.031336123981603854\ \(0\)\
\-\ including\\:\\ 0\\.030984213879778108\ \(0\)\
\-\ malignant\\:\\ 0\\.03086238391319073\ \(0\)\
\-\ complete\\:\\ 0\\.030348413539252852\ \(0\)\
\-\ because\\:\\ 0\\.030258591852429958\ \(0\)\
\-\ weight\\:\\ 0\\.03019191636693803\ \(0\)\
\-\ heart\\:\\ 0\\.030103917190378228\ \(0\)\
\-\ now\\:\\ 0\\.029720079248123393\ \(0\)\
\-\ 12\\:\\ 0\\.029596329050906048\ \(0\)\
\-\ neoplasm\\:\\ 0\\.02955552333995806\ \(0\)\
\-\ fever\\:\\ 0\\.02935472210561107\ \(0\)\
\-\ recent\\:\\ 0\\.029315191578988466\ \(0\)\
\-\ swelling\\:\\ 0\\.02913980869050233\ \(0\)\
\-\ initial\\:\\ 0\\.029044096905696804\ \(0\)\
\-\ radiation\\:\\ 0\\.028691017246282775\ \(0\)\
\-\ out\\:\\ 0\\.028458565694420665\ \(0\)\
\-\ superior\\:\\ 0\\.028148028764928276\ \(0\)\
\-\ day\\:\\ 0\\.027578319754028375\ \(0\)\
\-\ during\\:\\ 0\\.027423102811783923\ \(0\)\
\-\ fat\\:\\ 0\\.0269323053145203\ \(0\)\
\-\ wall\\:\\ 0\\.02633698973884223\ \(0\)\
\-\ on\\:\\ 0\\.026151806128182388\ \(0\)\
\-\ weeks\\:\\ 0\\.02594768163854581\ \(0\)\
\-\ lymphoma\\:\\ 0\\.025784991202766852\ \(0\)\
\-\ however\\:\\ 0\\.02562571502456276\ \(0\)\
\-\ trauma\\:\\ 0\\.02514421779221012\ \(0\)\
\-\ cell\\:\\ 0\\.02476686713637933\ \(0\)\
\-\ high\\:\\ 0\\.024606172835586724\ \(0\)\
\-\ over\\:\\ 0\\.02407405216853318\ \(0\)\
\-\ consistent\\:\\ 0\\.02347566840283463\ \(0\)\
\-\ increased\\:\\ 0\\.023412002472088647\ \(0\)\
\-\ man\\:\\ 0\\.02292103311542307\ \(0\)\
\-\ can\\:\\ 0\\.022719965888086845\ \(0\)\
\-\ other\\:\\ 0\\.022483908818905263\ \(0\)\
\-\ present\\:\\ 0\\.022216189472348494\ \(0\)\
\-\ it\\:\\ 0\\.022162223874066356\ \(0\)\
\-\ case\\:\\ 0\\.02175105351010614\ \(0\)\
\-\ but\\:\\ 0\\.021409559632142205\ \(0\)\
\-\ also\\:\\ 0\\.02036483608684519\ \(0\)\
\-\ normal\\:\\ 0\\.0176771527155033\ \(0\)\
\-\ an\\:\\ 0\\.01655595119551984\ \(0\)\
\-\ at\\:\\ 0\\.016353157041224135\ \(0\)\
\-\ this\\:\\ 0\\.014877021227059533\ \(0\)\
\-\ left\\:\\ 0\\.014768947734207344\ \(0\)\
\-\ no\\:\\ 0\\.01407911663954958\ \(0\)\
